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ender-Related
ifferences in Atrial Fibrillation*
harles R. Kerr, MD, FRCPC, FACC,
arin Humphries, MBA, DSC
ancouver, British Columbia, Canada
ender-related differences in coronary artery disease have
een long recognized (1,2). There are distinct differences in
linical presentation, outcome, and intensity of investigation
nd therapy. Less emphasis had previously been directed
owards gender differences in arrhythmias, although it has
ong been known that women have a higher mean heart rate
nd a longer QT interval (3). Differences in outcomes
etween men and women have been well described in the
QTS Registry (4,5).
See page 1298
In all age groups, men have a higher incidence of atrial
brillation than women. However, because the incidence of
trial fibrillation increases dramatically with age and because
here are more women in the population older than the age
f 75 years, the absolute number of women and men with
trial fibrillation in this age group is equal (6–9). In general,
omen present at an age approximately five years older than
en. This difference is analogous to the later presentation of
oronary artery disease in women. Women are more symp-
omatic than men, possibly because of faster heart rates and
mall body habitus (9,10). In the Canadian Registry of
trial Fibrillation (CARAF), women experienced a signif-
cantly increased frequency of symptomatic recurrences,
lthough there was no difference in electrocardiographically
ocumented occurrences (9).
Studies also have demonstrated differences in the clinical
haracteristics. The CARAF investigators demonstrated
hat, at the time of initial presentation of atrial fibrillation,
en have a higher burden of ischemic heart disease whereas
omen have a higher prevalence of hypertension and a
istory of thyroid dysfunction (9). The Framingham study
ohort suggested that there were higher incidences of
ongestive heart failure, valvular heart disease, and diabetes
6). Although women have a lower incidence of atrial
brillation, some studies have demonstrated a worse out-
ome and a higher rate of recurrence after cardioversion
11,12).
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.m
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ancouver, British Columbia, Canada.Differences in treatment patterns and drug-induced ad-
erse events also have been described. Several studies have
eported the underuse of anticoagulation in women older
han the age of 75, a subgroup with a particularly high risk
f thromboembolic events (9,13). However, the CARAF
nvestigators have found that women were 3.35 times more
ikely to experience a major bleed than men (9). Thus,
nticoagulation requires particularly careful monitoring in
omen. Proarrhythmia due to antiarrhythmic drugs (par-
icularly torsade de pointes induced by sotalol) is consider-
bly higher in women than in men and may adversely affect
he outcomes (14).
In this issue of the Journal, Rienstra et al. (10) provide an
mportant new insight into gender differences in the man-
gement of atrial fibrillation. Using data from the Rate
ontrol versus Electrical Cardioversion (RACE) study, the
uthors found no difference between cardiovascular morbid-
ty and mortality between women and men, but women who
ere randomized to the rhythm control strategy were at
ignificantly increased risk of the primary composite end
oint of death from cardiovascular cause, heart failure,
hromboembolic complications, bleeding, adverse affects
rom antiarrhythmic drugs, and pacemaker implantation
ompared with women who were randomized to rate
ontrol. This end point occurred in 11% of women assigned
o the rate control arm and 33% of those assigned to the
hythm control arm. Significant differences were observed in
our of the components of the composite end point: death
rom cardiovascular cause, heart failure, thromboembolic
omplications, and adverse affects from antiarrhythmic
rugs. There were no differences in outcomes between the
ate control versus rhythm control arms in men.
In addition to this important novel finding, the results of
his study were consistent with the findings from other
tudies in that the women affected were older, had a higher
ymptom load, had a poorer quality of life, and had an
ncreased prevalence of hypertension and diabetes. Men had
higher prevalence of coronary artery disease and previous
yocardial infarction.
This study has important implications. The RACE study
nd others have demonstrated that there is no advantage to
verall survival between a rate or rhythm control strategy
15–17). However, these studies all had elderly populations
nd, because both rate and rhythm control strategies had to
e acceptable alternatives, patient characteristics favored a
elatively asymptomatic group. There remains a need for
hythm control in many patients, particularly a younger
ctive population with a high symptomatic burden. One
lternative is pacemaker implantation and atrioventricular
ode ablation, but this strategy usually is recommended
fter failure of or intolerance to antiarrhythmic drugs. Thus,
he higher symptom burden in women with atrial fibrilla-
ion may force an increased emphasis on rhythm control.
This study tells us that care must be undertaken in
anaging women with a rhythm control strategy. The
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Editorial Comment October 4, 2005:1307–8argest absolute difference in end points between women in
he rate and rhythm control strategies occurred because of
dverse effects attributed to antiarrhythmic drugs, including
radycardia and proarrhythmic effects. Women are well
nown to have an increased propensity to drug-induced
orsade de pointes, particularly with sotalol (14,18). In
eneral, particular care should be given to elderly women
nd to those with renal dysfunction. In patients with
ignificant structural heart disease, hospitalization is recom-
ended for initiation of sotalol and other antiarrhythmic
rugs except amiodarone.
In this study, there was not an increased incidence of
leeding in women compared with men, an observation that
as been observed in other studies. This study has rein-
orced the fact that bleeds occur predominantly in patients
ith high international normalized ratio (INR) levels.
ther studies used more population-based, “real-world”
atient populations (9,13) whereas, in this closely regulated
tudy, INR control may have been more rigid. Anticoagu-
ation clinics, which are common in the Netherlands where
his study was conducted, also may lead to better control.
omen in a community setting may be more prone to
ariable INR control and may be more prone to bleeding.
hus, women may have a higher risk of bleeding in a
eneral population setting, suggesting increased vigilance
hould be given to maintain therapeutic INR levels.
An interesting finding is the lack of difference between
ate and rhythm control strategies with respect to quality of
ife. Quality of life in women with atrial fibrillation remains
ower than men and lower than control women in both arms
f this study. A possible explanation is that the sensitivity
nd side effects from antiarrhythmic drugs in the rhythm
ontrol arm may offset the high symptomatic burden of
alpitations and fatigue seen in the rate control arm.
Because of the decreased quality of life in women com-
ared with men, regardless of treatment strategy, a curative,
atheter-based procedure for atrial fibrillation appears very
ttractive. The rapidly evolving techniques and technology
nd the expansion of indications to include individuals with
ersistent and permanent atrial fibrillation in normal and
bnormal hearts, might be particularly useful to improve the
uality of life in women. One study has demonstrated that
omen are referred later after presentation for ablation of
upraventricular tachycardia (19). However, gender-related
ifferences in referral patterns and outcomes for ablation of
trial fibrillation have not been evaluated.
In summary, the current study should alert us to potential
ifferences in treatment strategies for women versus men
ith atrial fibrillation. Specifically, caution should be exer-
ised with the administration of antiarrhythmic drugs and
he use of rate control or nonpharmacologic rhythm control
hould be considered. Further studies are required to assesselative outcomes of curative ablation procedures between
en and women.
eprint requests and correspondence:Dr. Charles R. Kerr, Depart-
ent of Medicine, Division of Cardiology, St. Paul’s Hospital, Room
344, 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6
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